BLCM Projected Dividend Yield
Bellicum Pharmaceuticals Inc ( OTCBB : BLCM )Bellicum Pharmaceuticals is a biopharmaceutical company focused on discovering and developing controllable cellular immunotherapies for the treatment of various forms of cancer. Co. is developing chimeric antigen receptors (CAR)-T cell therapies, which are an approach in which a patient's or donor's T cells are genetically modified to carry CARs. By incorporating its switch technologies, Co. is developing product candidates in various areas of cellular immunotherapy including BPX-601, which is designed to treat solid tumors expressing prostate stem cell antigen; and BPX-603, which is designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen. 20 YEAR PERFORMANCE RESULTS |
BLCM Dividend History Detail BLCM Dividend News BLCM Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |